This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Lilly, and Merck & Co.

Management of Patients Treated With Immunotherapy

Beth Eaby-Sandy, MSN, CRNP, OCN®
University of Pennsylvania

Immunotherapy, one of the most important breakthroughs for cancer treatment in the past decade, is demonstrating its effectiveness across tumor types, including non–small cell lung cancer. This activity will provide information on the newest agents in the armamentarium for treating non–small cell lung cancer, including PD-1 inhibitor, and anti-CTLA4 immunotherapy. In addition, the discussion will include the recognition and management of potential immune-mediated adverse events unique to immune checkpoint inhibitors.

Related Activities

Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer: Skills Presentation

Management of Patients With Cytotoxic Chemotherapy

Targeted Therapies in Advanced Non–Small Cell Lung Cancer

Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

What is the role of EGFR mutations in patients with NSCLC?

What is T790m and describe its role in drug resistance?

What is ALK and how does it impact the treatment of NSCLC?

What should advanced practitioners know about the side effect profiles of targeted treatments for NSCLC?

What should pharmacists know about combining treatment agents for patients with NSCLC?

Bone Marrow Biopsy Demonstration Video

Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me